Lantheus (LNTH) Projected to Release Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lantheus to post earnings of $1.26 per share and revenue of $360.82 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the previous year, the business posted $1.57 EPS. Lantheus’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts expect Lantheus to post $4.54 EPS for the current fiscal year and $5.61 EPS for the next fiscal year.

Lantheus Stock Performance

LNTH opened at $100.10 on Thursday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $100.26 and its two-hundred day moving average price is $90.84. Lantheus has a 1-year low of $50.15 and a 1-year high of $111.86. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LNTH. Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $125.00 to $102.50 in a report on Monday, August 3rd. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and lowered their target price for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, William Blair set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus has a consensus rating of “Hold” and an average price target of $107.44.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.